Recent advances in management and treatment of hereditary angioedema

Pediatrics

Volumn 128, Issue 6, 2011, Pages 1173-1180

  Sardana, Niti ^a   Craig, Timothy J ^b  

^a WEILL CORNELL MEDICAL CENTER   (United States)

^b PENN STATE COLLEGE OF MEDICINE   (United States)

Author keywords

Bradykinin; C1 inhibitor; Hereditary angioedema; Prophylaxis; Treatment

Indexed keywords

ADRENALIN; AMINOCAPROIC ACID; ANDROGEN; ANTIFIBRINOLYTIC AGENT; ANTIHISTAMINIC AGENT; CETOR; COMPLEMENT COMPONENT C1S INHIBITOR; CORTICOSTEROID; DANAZOL; ECALLANTIDE; FRESH FROZEN PLASMA; ICATIBANT; METHYLTESTOSTERONE; NARCOTIC AGENT; OXANDROLONE; PLACEBO; RECOMBINANT COMPLEMENT COMPONENT C1S INHIBITOR; STANOZOLOL; TRANEXAMIC ACID; UNCLASSIFIED DRUG;

ACNE; ANAPHYLAXIS; ANGIONEUROTIC EDEMA; DRUG APPROVAL; DRUG CONTRAINDICATION; DRUG COST; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDICATION; DRUG SAFETY; DYSLIPIDEMIA; HEADACHE; HEART ARRHYTHMIA; HUMAN; HYDRATION; HYPERTENSION; HYPOTENSION; LIBIDO; LIVER NECROSIS; LIVER TUMOR; MENSTRUATION DISORDER; PALLIATIVE THERAPY; PATIENT CARE; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; REVIEW; RHABDOMYOLYSIS; SIDE EFFECT; THROMBOEMBOLISM; UNITED STATES; UNSPECIFIED SIDE EFFECT; VIRILIZATION; WEIGHT GAIN;

EID: 83155173304     PISSN: 00314005     EISSN: 10984275     Source Type: Journal    
DOI: 10.1542/peds.2011-0546     Document Type: Review

References (50)

1. Zuraw BL. Hereditary angioedema. N Engl J Med. 2008;359(10):1027-1036
2. Lumry WR, Castaldo AJ, Vernon MK, Blaustein MB, Wilson DA, Horn PT. The humanistic burden of hereditary angioedema: impact on health-related quality of life, productivity, and depression. Allergy Asthma Proc. 2010;31(5):407-414
3. Gosswein T, Kocot A, Emmert G, et al. Mutational spectrum of the C1INH (SERPING1) gene in patients with hereditary angioedema. Cytogenet Genome Res. 2008;121(3-4):181-188
4. Dewald G, Bork K. Missense mutations in the coagulation factor XII (Hageman factor) gene in hereditary angioedema with normal C1 inhibitor. Biochem Biophys Res Commun. 2006;343(4):1286-1289
5. Bork K, Guel D, Hardt J, Dewald G. Hereditary angioedema with normal C1 inhibitor: clinical symptoms and course. Am J Med. 2007;120(11):987-992 (Pubitemid 47633496)
6. Bork K, Wulff K, Hardt J, Witzke G, Staubach P. Hereditary angioedema caused by missense mutations in the factor XII gene: clinical features, trigger factors, and therapy. J Allergy Clin Immunol. 2009;124(1):129-134
7. Nagy N, Greaves MW, Tanaka A, McGrath JA, Grattan CE. Recurrent European missense mutation in the F12 gene in a British family with type III hereditary angioedema. J Dermatol Sci. 2009;56(1):62-64
8. Agostoni A, Cicardi M. Hereditary and acquired C1-inhibitor deficiency: biological and clinical characteristics in 235 patients. Medicine (Baltimore). 1992;71(4):206-215
9. Bork K, Meng G, Staubach P, Hardt J. Hereditary angioedema: new findings concerning symptoms, affected organs, and course. Am J Med. 2006;119(3):267-274 (Pubitemid 43255068)
10. Göring HD, Bork K, Späth PJ, et al. Hereditary angioedema in the German-speaking region [in German]. Hautarzt. 1998;49(2):114-122 (Pubitemid 28116522)
11. Lunn ML, Santos CB, Craig TJ. Is there a need for clinical guidelines in the United States for the diagnosis of hereditary angioedema and the screening of family members of affected patients? Ann Allergy Asthma Immunol. 2010;104(3):211-214
12. Bork K, Siedlecki K, Bosch S, Schopf RE, Kreuz W. Asphyxiation by laryngeal edema in patients with hereditary angioedema. Mayo Clin Proc. 2000;75(4):349-354 (Pubitemid 30187107)
13. Bork K, Hardt J, Schicketanz KH, Ressel N. Clinical studies of sudden upper airway obstruction in patients with hereditary angioedema due to C1 esterase inhibitor deficiency. Arch Intern Med. 2003;163(10):1229-1235 (Pubitemid 36613077)
14. Bowen T, Brosz J, Brosz K, et al. 2010 international consensus algorithm for the diagnosis, therapy and management of hereditary angioedema. Allergy Asthma Clin Immunol. 2010;6(1):24
15. Prematta M, Gibbs JG, Pratt EL, Stoughton TR, Craig TJ. Fresh frozen plasma for the treatment of hereditary angioedema. Ann Allergy Asthma Immunol. 2007;98(4):383-388 (Pubitemid 46582131)
16. Banerji A, Sloane DE, Sheffer AL. Hereditary angioedema: a current state-of-the-art review, V - attenuated androgens for the treatment of hereditary angioedema. Ann Allergy Asthma Immunol. 2008;100(1 suppl 2):S19-S22
17. Cicardi M, Bergamaschini L, Cugno M, Hack E, Agostoni G, Agostoni A. Long-term treatment of hereditary angioedema with attenuated androgens: a survey of a 13-year experience. J Allergy Clin Immunol. 1991;87(4):768-773
18. Church JA. Oxandrolone treatment of childhood hereditary angioedema. Ann Allergy Asthma Immunol. 2004;92(3):377-378 (Pubitemid 38380797)
19. Farkas H, Varga L, Szeplaki G, Visy B, Harmat G, Bowen T. Management of hereditary angioedema in pediatric patients. Pediatrics. 2007;120(3). Available at: www.pediatrics.org/cgi/content/full/120/3/e713
20. Craig T. Assessment of danazol and other androgens in the treatment of hereditary angioedema. Allergy Asthma Proc. 2008;29(3):225-231
21. Farkas H, Gyeney L, Gidofalvy E, Fust G, Varga L. The efficacy of short-term danazol prophylaxis in hereditary angioedema patients undergoing maxillofacial and dental procedures. J Oral Maxillofac Surg. 1999;57(4):404-408 (Pubitemid 29165269)
22. Jaffe CJ, Atkinson JP, Gelfand JA, Frank MM. Hereditary angioedema: the use of fresh frozen plasma for prophylaxis in patients undergoing oral surgery. J Allergy Clin Immunol. 1975;55(6):386-393
23. De Serres J, Gröner A, Lindner J. Safety and efficacy of pasteurized C1 inhibitor concentrate (Berinert P) in hereditary angioedema: a review. Transfus Apher Sci. 2003;29(3):247-254 (Pubitemid 37321355)
24. Martinez-Saguer I, Rusicke E, Aygoren-Pursun E, von Hentig N, Klingebiel T, Kreuz W. Pharmacokinetic analysis of human plasma-derived pasteurized C1-inhibitor concentrate in adults and children with hereditary angioedema: a prospective study. Transfusion. 2010;50(2):354-360
25. Craig TJ, Levy RJ, Wasserman RL, et al. Efficacy of human C1 esterase inhibitor concentrate compared with placebo in acute hereditary angioedema attacks. J Allergy Clin Immunol. 2009;124(4):801-808
26. Bork K, Barnstedt SE. Treatment of 193 episodes of laryngeal edema with C1 inhibitor concentrate in patients with hereditary angioedema. Arch Intern Med. 2001;161(5):714-718 (Pubitemid 32200225)
27. Bork K, Meng G, Staubach P, Hardt J. Treatment with C1 inhibitor concentrate in abdominal pain attacks of patients with hereditary angioedema. Transfusion. 2005;45(11):1774-1784 (Pubitemid 43923905)
28. Zuraw BL, Busse PJ, White M, et al. Nanofiltered C1 inhibitor concentrate for treatment of hereditary angioedema. N Engl J Med. 2010;363(6):513-522
29. Farkas H, Jakab L, Temesszentandrasi G, et al. Hereditary angioedema: a decade of human C1-inhibitor concentrate therapy. J Allergy Clin Immunol. 2007;120(4):941-947 (Pubitemid 47531846)
30. Zuraw B, Cicardi M, Levy RJ, et al. Recombinant human C1-inhibitor for the treatment of acute angioedema attacks in patients with hereditary angioedema. J Allergy Clin Immunol. 2010;126(4):821-827
31. van Doorn MB, Burggraaf J, van Dam T, et al. A phase I study of recombinant human C1 inhibitor in asymptomatic patients with hereditary angioedema. J Allergy Clin Immunol. 2005;116(4):876-883 (Pubitemid 41400555)
32. Choi G, Soeters MR, Farkas H, et al. Recombinant human C1-inhibitor in the treatment of acute angioedema attacks. Transfusion. 2007;47(6):1028-1032 (Pubitemid 46802091)
33. Bernstein JA. Hereditary angioedema: a current state-of-the-art review, VIII - current status of emerging therapies. Ann Allergy Asthma Immunol. 2008;100(1 suppl 2):S41-S46
34. Williams A, Baird LG. DX-88 and HAE: a developmental perspective. Transfus Apher Sci. 2003;29(3):255-258 (Pubitemid 37315589)
35. Markland W, Ley AC, Ladner RC. Iterative optimization of high-affinity protease inhibitors using phage display: 2. Plasma kallikrein and thrombin. Biochemistry. 1996;35(24):8058-8067 (Pubitemid 26202548)
36. Ley AC, Markland W, Ladner RC. Obtaining a family of high-affinity, high-specificity protein inhibitors of plasmin and plasma kallikrein. Mol Divers. 1996;2(1-2):119-124 (Pubitemid 126817074)
37. Schneider L, Lumry W, Vegh A, Williams AH, Schmalbach T. Critical role of kallikrein in hereditary angioedema pathogenesis: a clinical trial of ecallantide, a novel kallikrein inhibitor. J Allergy Clin Immunol. 2007;120(2):416-422 (Pubitemid 47102386)
38. Zuraw BL. Novel therapies for hereditary angioedema. Immunol Allergy Clin North Am. 2006;26(4):691-708 (Pubitemid 44666311)
39. Levy R, Li H, Hsu FI, Horn P, Roberts J. Results of a 2-stage, phase 3 pivotal trial, EDEMA 3: a study of subcutaneous DX-88 (Ecallantide), a plasma kallikrein inhibitor, in patients with hereditary angioedema (HAE) [abstr]. J Allergy Clin Immunol. 2008;121(2):S231
40. Cicardi M, Levy RJ, McNeil DL, et al. Ecallantide for the treatment of acute attacks in hereditary angioedema. N Engl J Med. 2010;363(6):523-531
41. Zuraw BL. HAE therapies: past present and future. Allergy Asthma Clin Immunol. 2010;6(1):23
42. Hock FJ, Wirth K, Albus U, et al. Hoe 140 a new potent and long acting bradykininantagonist: in vitro studies. Br J Pharmacol. 1991;102(3):769-773
43. Han ED, MacFarlane RC, Mulligan AN, Scafidi J, Davis AE. Increased vascular permeability in C1 inhibitor-deficient mice mediated by the bradykinin type 2 receptor. J Clin Invest. 2002;109(8):1057-1063 (Pubitemid 34408580)
44. Wagner F, Rosenkranz B, Knolle J. Absolute bioavailability of subcutaneously administered icatibant, a selective and potent bradykinin B2 receptor antagonist [abstr]. J Allergy Clin Immunol. 2007;119(1):S274
45. Bork K, Frank J, Grundt B, Schlattmann P, Nussberger J, Kreuz W. Treatment of acute edema attacks in hereditary angioedema with a bradykinin receptor-2 antagonist (icatibant). J Allergy Clin Immunol. 2007;119(6):1497-1503 (Pubitemid 46855846)
46. Kalra N, Craig T. Update on recent trials in the treatment of hereditary angioedema. Clin Investig (Lond). 2011;1(3):439-445
47. Dagen C, Craig T. Treatment of hereditary angioedema: items that need to be addressed in practice parameter. Allergy Asthma Clin Immunol. 2010;6(1):11
48. Frank MM, Jiang H. New therapies for hereditary angioedema: disease outlook changes dramatically. J Allergy Clin Immunol. 2008;121(1):272-280
49. Cicardi M, Banerji A, Bracho F, et al. Icatibant, a new bradykinin-receptor antagonist, in hereditary angioedema [published correction appears in N Engl JMed. 2010;363(15):1486]. N Engl J Med. 2010;363(6):532-541
50. Prematta M, Kemp J, Gibbs J, Mende C, Rhoads C, Craig T. Frequency, timing and type of prodromal symptoms associated with hereditary angioedema attacks. Allergy Asthma Proc. 2009;30(5):506-511